Literature DB >> 29281578

Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets.

Robert Zeiser1, Bruce R Blazar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29281578     DOI： 10.1056/NEJMra1703472

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  167 in total

1.  Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.

Authors:  Anusara Daenthanasanmak; Supinya Iamsawat; Paramita Chakraborty; Hung D Nguyen; David Bastian; Chen Liu; Shikhar Mehrotra; Xue-Zhong Yu
Journal:  Blood       Date:  2018-12-04       Impact factor: 22.113

Review 2.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

Review 3.  Biology-driven developments in the therapy of acute graft-versus-host disease.

Authors:  Robert Zeiser
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

4.  Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.

Authors:  Jennifer S Whangbo; Haesook T Kim; Sarah Nikiforow; John Koreth; Ana C Alho; Bryn Falahee; Soomin Kim; Katharine Dusenbury; Marie J Fields; Carol G Reynolds; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  Blood Adv       Date:  2019-04-09

Review 5.  The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.

Authors:  Hong-Gang Ren; Djamilatou Adom; Sophie Paczesny
Journal:  Expert Rev Clin Immunol       Date:  2018-04-19       Impact factor: 4.473

Review 6.  Biomarkers for posttransplantation outcomes.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2018-04-05       Impact factor: 22.113

7.  Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.

Authors:  Katelyn Paz; Ryan Flynn; Jing Du; Jun Qi; Leo Luznik; Ivan Maillard; Kelli P MacDonald; Geoffrey R Hill; Jonathan S Serody; William J Murphy; Peter T Sage; Arlene H Sharpe; David Miklos; Corey S Cutler; John Koreth; Joseph H Antin; Robert J Soiffer; Jerome Ritz; James E Bradner; Ari M Melnick; Bruce R Blazar
Journal:  Blood       Date:  2018-10-02       Impact factor: 22.113

8.  Tissue-resident PSGL1loCD4+ T cells promote B cell differentiation and chronic graft-versus-host disease-associated autoimmunity.

Authors:  Xiaohui Kong; Deye Zeng; Xiwei Wu; Bixin Wang; Shijie Yang; Qingxiao Song; Yongping Zhu; Martha Salas; Hanjun Qin; Ubaydah Nasri; Karen M Haas; Arthur D Riggs; Ryotaro Nakamura; Paul J Martin; Aimin Huang; Defu Zeng
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

9.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04

10.  Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease.

Authors:  Kristina Maas-Bauer; Chrissoula Kiote-Schmidt; Hartmut Bertz; Petya Apostolova; Ralph Wäsch; Gabriele Ihorst; Jürgen Finke; Robert Zeiser
Journal:  Bone Marrow Transplant       Date:  2020-11-17       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.